ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 9, 2024 and March 25, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before August 10, 2026. According to the Complaint, the Company made false and misleading statements to the market. ADMA engaged in a related party transaction it failed to disclose. The Company utilized channel stuffing to create the appearance of revenue. The Company failed to maintain appropriate internal controls. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about ADMA, investors suffered damages.